The SIPPET Study Answers an Important Question
Researchers have taken an important step toward understanding inhibitor development. Results from a randomized, controlled trial, called the SIPPET study, demonstrated that previously untreated patients with severe hemophilia A treated with recombinant factor VIII (FVIII) have a higher risk of developing inhibitors compared to patients treated with plasma-derived FVIII containing von Willebrand factor (VWF).1
THE ROAD TO SIPPET: A HISTORICAL PERSPECTIVE
Over the years, medical research has tried to answer an important question: Does the source of FVIII product used in replacement therapy impact the likelihood of inhibitor development? Studies have reported varying rates of inhibitor development with 2 types of FVIII products, plasma-derived and recombinant.1-4
Researchers Wight and Paisley reviewed the best evidence that was available in the published literature in 2003. Within the 50 studies, a subset of 13 examined inhibitor incidence in 801 previously untreated patients who received a single FVIII product, and found that plasma-derived FVIII had a lower cumulative risk of inhibitors vs recombinant FVIII.
CANAL stands for Concerted Action on Neutralizing Antibodies in severe hemophilia A. It was a retrospective cohort study that included 316 previously untreated patients with severe hemophilia A. CANAL concluded that the risk of inhibitor development was slightly lower with plasma-derived products compared with recombinant products. But the difference was not statistically significant.
THE QUESTION REMAINED UNANSWERED1
SIPPET STUDY RESULTS1
The study demonstrated a significantly higher incidence of inhibitors with recombinant FVIII vs plasma-derived FVIII containing VWF. The rate of inhibitor development with recombinant FVIII was nearly double that with plasma-derived FVIII/VWF (HR=1.87, 95% CI:1.17-2.96). The authors concluded that these results may have implications on how physicians plan treatment in previously untreated patients with hemophilia A.
Cumulative incidence of inhibitor development1
Previously untreated patients with inhibitors
Recombinant FVIII had an 87% higher rate of inhibitor development than plasma-derived FVIII/VWF. (Cox regression HR=1.87, 95% CI: 1.17-2.96)1
Sign up to receive access to the full SIPPET study, as well as updates about hemophilia, inhibitors, and the latest clinical data.
- Peyvandi F, Mannucci PM, Garagiola I, et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med. 2016;374(21):2054-2064.
- Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia. 2003;9:418-435.
- Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM for the CANAL Study Group. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4648-4654.
- Gouw SC, van der Bom JG, Ljung R, et al, for; the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. New Engl J Med. 2013;368(3):231-239.
- National Hemophilia Foundation. MASAC Update on SIPPET. National Hemophilia Foundation website. https://www.hemophilia.org/Newsroom/NHF-Community-News/MASAC-Update-on-SIPPET. Published March 9, 2016. Accessed May 25, 2016.